{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:41:23Z","timestamp":1790628083884,"version":"4.1.0"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T00:00:00Z","timestamp":1658793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Autoinflammatory diseases are characterized by abnormalities that prevent innate immune cells from producing autoantibodies. While interleukin (IL)-6 is not directly associated with inflammasomes, like IL-1\u03b2 or IL-18, it plays an important role in the pathogenesis of autoinflammatory diseases. Studies of autoinflammatory diseases, such as familial Mediterranean fever, cryopyrin-associated periodic syndrome, and tumor necrosis factor receptor-associated periodic syndrome, have shown IL-6 to be a promising therapeutic target. It has also been suggested that inhibition of IL-6 may have a therapeutic effect on amyloidosis, which is frequently associated with these chronic inflammatory diseases. In this study, we discuss the most recent research on the role of IL-6 in autoinflammatory diseases and its potential as a therapeutic target in their treatment.<\/jats:p>","DOI":"10.3389\/fimmu.2022.956795","type":"journal-article","created":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T04:58:45Z","timestamp":1658811525000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":32,"title":["Interleukin-6 inhibition in the treatment of autoinflammatory diseases"],"prefix":"10.3389","volume":"13","author":[{"given":"Tomohiro","family":"Koga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/13497413.2018.1481579","article-title":"Familial Mediterranean fever: overview of pathogenesis, clinical features and management","volume":"41","author":"Migita","year":"2018","journal-title":"Immunol Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1182\/asheducation-2005.1.74","article-title":"Hereditary periodic fever syndromes","volume":"1","author":"Kastner","year":"2005","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.hoc.2017.09.003","article-title":"The role of interleukin-6 in castleman disease","volume":"32","author":"Yoshizaki","year":"2018","journal-title":"Hematol Oncol Clin North Am"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.4.1243.bloodjournal8641243","article-title":"Interleukin-6 family of cytokines and gp130","volume":"86","author":"Kishimoto","year":"1995","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/stem.5530120303","article-title":"Signal transduction through gp130 that is shared among the receptors for the interleukin 6 related cytokine subfamily","volume":"12","author":"Hirano","year":"1994","journal-title":"Stem Cells"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2018.1532383","article-title":"A benefit and the prospects of IL-6 inhibitors in idiopathic multicentric castleman's disease","volume":"29","author":"Koga","year":"2019","journal-title":"Mod Rheumatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial","volume":"371","author":"Smolen","year":"2008","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213920","article-title":"Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial","volume":"77","author":"Kaneko","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211878","article-title":"Efficacy and safety of tocilizumab in patients with refractory takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study)","volume":"77","author":"Nakaoka","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant-cell arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000002053","article-title":"Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia","volume":"45","author":"Fitzgerald","year":"2017","journal-title":"Crit Care Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00081-3","article-title":"Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial","volume":"9","author":"Soin","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/25785826.2018.1524105","article-title":"Diagnosis and treatment of autoinflammatory diseases in adults: a clinical approach from rheumatologists","volume":"41","author":"Koga","year":"2018","journal-title":"Immunol Med"},{"key":"B14","article-title":"Levels of interleukin-6 (IL-6) and its soluble receptor (sIL-6R) in familial Mediterranean fever (FMF) patients and their first degree relatives","volume":"22","author":"Oktem","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.berh.2017.12.001","article-title":"Periodic fever syndromes","volume":"31","author":"Lachmann","year":"2017","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0020014","article-title":"Role of IL-1 beta in the development of human T(H)17 cells: lesson from NLPR3 mutated patients","volume":"6","author":"Lasiglie","year":"2011","journal-title":"PLoS One"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/s0092-8674(00)80721-7","article-title":"Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes","volume":"97","author":"McDermott","year":"1999","journal-title":"Cell"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kei090","article-title":"Systemic cytokine levels and the effects of etanercept in TNF receptor-associated periodic syndrome (TRAPS) involving a C33Y mutation in TNFRSF1A","volume":"45","author":"Nowlan","year":"2006","journal-title":"Rheumatol (Oxford)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/art.30215","article-title":"Role of interleukin-6 in a patient with tumor necrosis factor receptor-associated periodic syndrome: assessment of outcomes following treatment with the anti-interleukin-6 receptor monoclonal antibody tocilizumab","volume":"63","author":"Vaitla","year":"2011","journal-title":"Arthritis Rheumatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.5152\/eurjrheumatol.2014.14053","article-title":"Successful treatment of tumor necrosis factor receptor-associated periodic syndrome (TRAPS) with tocilizumab: A case report","volume":"2","author":"Akasbi","year":"2015","journal-title":"Eur J Rheumatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.54.3371","article-title":"A case presenting with the clinical characteristics of tumor necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS) without TNFRSF1A mutations successfully treated with tocilizumab","volume":"54","author":"Hosoya","year":"2015","journal-title":"Intern Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)09408-7","article-title":"Familial Mediterranean fever","volume":"351","author":"Ben-Chetrit","year":"1998","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20032234","article-title":"The PYRIN connection: novel players in innate immunity and inflammation","volume":"200","author":"Stehlik","year":"2004","journal-title":"J Exp Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20142384","article-title":"Aberrant actin depolymerization triggers the pyrin inflammasome and autoinflammatory disease that is dependent on IL-18, not IL-1beta","volume":"212","author":"Kim","year":"2015","journal-title":"J Exp Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-004-0925-4","article-title":"Continuity of cytokine activation in patients with familial Mediterranean fever","volume":"23","author":"Bagci","year":"2004","journal-title":"Clin Rheumatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003449","article-title":"Multiple serum cytokine profiling to identify combinational diagnostic biomarkers in attacks of familial Mediterranean fever","volume":"95","author":"Koga","year":"2016","journal-title":"Med (Baltimore)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwr460","article-title":"Triggers for attacks in familial Mediterranean fever: application of the case-crossover design","volume":"175","author":"Yenokyan","year":"2012","journal-title":"Am J Epidemiol"},{"key":"B28","article-title":"Triggering factors for febrile attacks in Japanese patients with familial Mediterranean fever","author":"Kishida","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208690","article-title":"EULAR recommendations for the management of familial Mediterranean fever","volume":"75","author":"Ozen","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1089\/jir.1998.18.479","article-title":"Estrogen inhibits interleukin-1beta-induced interleukin-6 production by human osteoblast-like cells","volume":"18","author":"Koka","year":"1998","journal-title":"J Interferon Cytokine Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2020.1800558","article-title":"Genetic and clinical characteristics associated with efficacy and retention rates of colchicine in Japanese patients with familial Mediterranean fever: A single-center observational study","volume":"31","author":"Hara","year":"2021","journal-title":"Mod Rheumatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2013.04.011","article-title":"Evidence-based recommendations for the practical management of familial Mediterranean fever","volume":"43","author":"Hentgen","year":"2013","journal-title":"Semin Arthritis Rheumatol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1056\/NEJM197212212872514","article-title":"Colchicine for familial Mediterranean fever","volume":"287","author":"Goldfinger","year":"1972","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/BF00441519","article-title":"Familial Mediterranean fever (recurrent hereditary polyserositis) in children: analysis of 88 cases","volume":"148","author":"Majeed","year":"1989","journal-title":"Eur J Pediatr"},{"key":"B35","article-title":"About colchicine compliance, resistance and virulence","volume":"27","author":"Ben-Chetrit","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-86-2-162","article-title":"Efficacy of intermittent colchicine therapy in familial Mediterranean fever","volume":"86","author":"Wright","year":"1977","journal-title":"Ann Intern Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.744780","article-title":"Real-life indications of interleukin-1 blocking agents in hereditary recurrent fevers: Data from the JIRcohort and a literature review","volume":"12","author":"Vinit","year":"2021","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.619257","article-title":"IL-1 inhibitors in the treatment of monogenic periodic fever syndromes: From the past to the future perspectives","volume":"11","author":"Malcova","year":"2020","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.nefro.2015.06.026","article-title":"Anakinra induces complete remission of nephrotic syndrome in a patient with familial mediterranean fever and amyloidosis","volume":"36","author":"Sevillano","year":"2016","journal-title":"Nefrologia"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2003.12.096","article-title":"IL-6 plays a critical role in the synergistic induction of human serum amyloid a (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system","volume":"314","author":"Hagihara","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2016.1162261","article-title":"Biologic therapy in familial Mediterranean fever","volume":"26","author":"Koga","year":"2016","journal-title":"Mod Rheumatol"},{"key":"B42","article-title":"Interleukin-6 targeting therapy in familial Mediterranean fever","volume":"31","author":"Fujikawa","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"610","DOI":"10.3109\/14397595.2014.908810","article-title":"Successful treatment with humanized anti-interleukin-6 receptor antibody (tocilizumab) in a case of AA amyloidosis complicated by familial Mediterranean fever","volume":"26","author":"Hamanoue","year":"2016","journal-title":"Mod Rheumatol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.12776","article-title":"Tocilizumab is effective in a familial Mediterranean fever patient complicated with histologically proven recurrent fasciitis and myositis","volume":"20","author":"Umeda","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.1097\/RHU.0000000000001271","article-title":"Protracted febrile myalgia syndrome treated with tocilizumab","volume":"27","author":"Honda","year":"2021","journal-title":"J Clin Rheumatol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu474","article-title":"Tocilizumab in the treatment of patients with AA amyloidosis secondary to familial Mediterranean fever","volume":"54","author":"Yilmaz","year":"2015","journal-title":"Rheumatol (Oxford)"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2019.1709258","article-title":"The assessment of tocilizumab therapy on recurrent attacks of patients with familial Mediterranean fever: A retrospective study of 15 patients","volume":"31","author":"Colak","year":"2021","journal-title":"Mod Rheumatol"},{"key":"B48","doi-asserted-by":"crossref","DOI":"10.55563\/clinexprheumatol\/fgx9vv","article-title":"A randomized, double-blind, placebo-controlled phase III trial on the efficacy and safety of tocilizumab in patients with familial Mediterranean fever","author":"Koga","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1097\/01.RHU.0000442576.41537.de","article-title":"Interleukin 6 blockade for hyperimmunoglobulin d and periodic fever syndrome","volume":"20","author":"Shendi","year":"2014","journal-title":"J Clin Rheumatol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220876","article-title":"Tocilizumab in VEXAS relapsing polychondritis: a single-center pilot study in Japan","volume":"80","author":"Kirino","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010177","article-title":"Therapeutic options in VEXAS syndrome: insights from a retrospective series","volume":"137","author":"Bourbon","year":"2021","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2026834","article-title":"Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease","volume":"383","author":"Beck","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.956795\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,12]],"date-time":"2023-02-12T10:45:53Z","timestamp":1676198753000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.956795\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,26]]},"references-count":52,"alternative-id":["10.3389\/fimmu.2022.956795"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.956795","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,26]]},"article-number":"956795"}}